← Leaderboards
Gerald M. Reaven
Stanford University
$10,248,115
Attributed
$10,248,115
Total exposure
34
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $983.4K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$10,248,115 · 34
By mechanism
R01$5,391,635 · 5
M01$2,430,163 · 28
U01$2,426,317 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Thomas N Robinson$40,790,008
- Tracey McLaughlin$5,362,409
- Brian Andrew Hargreaves$16,291,706
- Fredric B. Kraemer$7,721,140
- Joshua Wiley Knowles$7,436,668
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchInsulin Sensitivity /ResistanceInsulinHyperinsulinismGlucose MetabolismInsulin ResistanceNoninsulin Dependent Diabetes MellitusCoronary DisorderAdipose TissueObesityCardiovascular Disorder RiskGlucose ToleranceGlucoseResearch PersonnelMediatingLinkMetabolicLipid MetabolismDefectNutrition Related TagPlasmaComputer Retrieval Of Information On Scientific Projects DatabaseGrant
Grant awards (61)
Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin resistance$588,079
U01 · FY2014 · HL · contact PI
Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin resistance$584,257
U01 · FY2013 · HL · contact PI
Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin resistance$626,943
U01 · FY2012 · HL · contact PI
Beneficial Effect of Salicylates: Insulin action, Secretion or Clearance?$356,400
R01 · FY2012 · DK · contact PI
Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin resistance$627,038
U01 · FY2011 · HL · contact PI
Beneficial Effect of Salicylates: Insulin action, Secretion or Clearance?$356,400
R01 · FY2011 · DK · contact PI
Beneficial effect of salicylates: insulin action, secretion or clearance?$360,000
R01 · FY2010 · DK · contact PI
Integrating the Metabolic and Genetic Faces of Obesity$323,553
R01 · FY2008 · DK · contact PI
CLINICAL TRIAL: FENOFIBRATE AND ROSIGLITAZONE IN INSULIN RESISTANT DYSLIPIDEMIC$13,539
M01 · FY2008 · RR · contact PI
LIPEMIA: CARBOHYDRATE AND GLYCERIDE METABOLISM$6,144
M01 · FY2008 · RR · contact PI
RELATIONSHIP BETWEEN INSULIN RESISTANCE & EARLY DEV OF ATHEROGENESIS$5,006
M01 · FY2008 · RR · contact PI
IN VIVO STUDIES OF INSULIN SECRETION AND RESISTANCE IN FAMILIES$341
M01 · FY2008 · RR · contact PI
Integrating the Metabolic and Genetic Faces of Obesity$330,156
R01 · FY2007 · DK · contact PI
CARDIOVASCULAR DISEASE RISK IN INSULIN RESISTANT DYSLIPIDEMIC INDIVIDUALS$153,308
M01 · FY2007 · RR · contact PI
RELATIONSHIP BETWEEN INSULIN RESISTANCE & EARLY DEV OF ATHEROGENESIS$93,038
M01 · FY2007 · RR · contact PI
LIPEMIA: CARBOHYDRATE AND GLYCERIDE METABOLISM$73,728
M01 · FY2007 · RR · contact PI
PIOGLITAZONE ATTENUATE CORONARY HEART DISEASE RISK FACTORS IN SMOKERS$42,131
M01 · FY2007 · RR · contact PI
IN VIVO STUDIES OF INSULIN SECRETION AND RESISTANCE IN FAMILIES$19,310
M01 · FY2007 · RR · contact PI
Integrating the Metabolic and Genetic Faces of Obesity$336,189
R01 · FY2006 · DK · contact PI
CAN PIOGLITAZONE ATTENUATE CORONARY HEART DISEASE RISK FACTORS?$89,845
M01 · FY2006 · RR · contact PI
ABILITY OF FENOFIBRATE AND ROSIGLITAZONE TO DECREASE CARDIOVASCULAR DISEASE$88,066
M01 · FY2006 · RR · contact PI
LIPEMIA: CARBOHYDRATE AND GLYCERIDE METABOLISM$40,030
M01 · FY2006 · RR · contact PI
RELATIONSHIP BETWEEN INSULIN RESISTANCE & EARLY DEVELOPMENT OF ATHEROGENESIS$28,911
M01 · FY2006 · RR · contact PI
IN VIVO STUDIES OF INSULIN SECRETION AND RESISTANCE IN FAMILIES$16,456
M01 · FY2006 · RR · contact PI
Integrating the Metabolic and Genetic Faces of Obesity$345,168
R01 · FY2005 · DK
ABILITY OF FENOFIBRATE AND ROSIGLITAZONE TO DECREASE CARDIOVASCULAR DISEASE$108,253
M01 · FY2005 · RR
CAN PIOGLITAZONE ATTENUATE CORONARY HEART DISEASE RISK FACTORS?$97,896
M01 · FY2005 · RR
LIPEMIA: CARBOHYDRATE AND GLYCERIDE METABOLISM$77,849
M01 · FY2005 · RR
RELATIONSHIP BETWEEN INSULIN RESISTANCE &EARLY DEVELOPMENT OF ATHEROGENESIS$6,348
M01 · FY2005 · RR
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES$499,676
R01 · FY2004 · HL
Insulin Resistance, Weight Loss and Cardiovascular Risk$430,257
M01 · FY2004 · RR
Relationship between Insulin Resistance &Atherogenesis$119,714
M01 · FY2004 · RR
Can Pioglitazone Attenuate Coronary Heart Disease Risk Factors in Insulin$112,898
M01 · FY2004 · RR
Lipemia: Carbohydrate and Glyceride Metabolism$68,450
M01 · FY2004 · RR
In Vivo Studies of Insulin Secretion and Resistance$32,595
M01 · FY2004 · RR
Muscle Insulin Resistance: "Not-so-Thrifty" Phenotype$22,224
M01 · FY2004 · RR
Comparison of the Ability of Fenofibrate &Rosiglitazone$5,630
M01 · FY2004 · RR
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES$499,676
R01 · FY2003 · HL
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES$499,676
R01 · FY2002 · HL
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES$499,676
R01 · FY2001 · HL
RELATIONSHIP BETWEEN INSULIN RESISTANCE AND EARLY DEVELOPMENT OF ATHEROGENESIS$134,676
M01 · FY2001 · RR
POSTPRANDIAL LIPEMIA RESPONSE TO GEMFIBROZIL VS PRAVASTATIN$134,676
M01 · FY2001 · RR
INSULIN RESISTANCE IN NONINSULIN-DEPENDENT DIABETES MELLITUS (TYPE II)$134,676
M01 · FY2001 · RR
INSULIN RESISTANCE, HYPERINSULINEMIA &WEIGHT LOSS$134,676
M01 · FY2001 · RR
INSULIN RESISTANCE, DIETARY CHOLESTEROL AND CHOLESTEROL CONCENTRATION$134,676
M01 · FY2001 · RR
INSULIN RESISTANCE IN NONINSULIN-DEPENDENT DIABETES MELLITUS (TYPE II)$0
M01 · FY2001 · RR
INSULIN RESISTANCE, HYPERINSULINEMIA &WEIGHT LOSS$0
M01 · FY2001 · RR
POSTPRANDIAL LIPEMIA RESPONSE TO GEMFIBROZIL VS PRAVASTATIN$0
M01 · FY2001 · RR
RELATIONSHIP BETWEEN INSULIN RESISTANCE AND EARLY DEVELOPMENT OF ATHEROGENESIS$0
M01 · FY2001 · RR
INSULIN RESISTANCE, DIETARY CHOLESTEROL AND CHOLESTEROL CONCENTRATION$0
M01 · FY2001 · RR
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES$512,700
R01 · FY2000 · HL
LIPEMIA--CARBOHYDRATE AND GLYCERIDE METABOLISM$260,794
R01 · FY2000 · HL
INSULIN RESISTANCE IN NONINSULIN DEPENDENT DIABETES$211,571
R01 · FY2000 · DK
INSULIN RESISTANCE IN NONINSULIN-DEPENDENT DIABETES MELLITUS (TYPE II)$602
M01 · FY2000 · RR
EFFECTS OF FAT &CARBOHYDRATE ON POSTPRANDIAL LIPEMIA$602
M01 · FY2000 · RR
INSULIN RESISTANCE, HYPERINSULINEMIA &WEIGHT LOSS$602
M01 · FY2000 · RR
POSTPRANDIAL LIPEMIA RESPONSE TO GEMFIBROZIL VS PRAVASTATIN$602
M01 · FY2000 · RR
GLUCOPHAGE EFFECTS ON CORONARY HEART DISEASE IN NON INSULIN DIABETES$602
M01 · FY2000 · RR
RELATIONSHIP BETWEEN INSULIN RESISTANCE AND EARLY DEVELOPMENT OF ATHEROGENESIS$602
M01 · FY2000 · RR
INSULIN RESISTANCE, DIETARY CHOLESTEROL AND CHOLESTEROL CONCENTRATION$602
M01 · FY2000 · RR
LIPEMIA--CARBOHYDRATE AND GLYCERIDE METABOLISM$602
M01 · FY2000 · RR